Scinai Immunotherapeutics Ltd. (SCNI) Stock

NASDAQ: SCNIDevelops immunotherapies for cancer treatment, focusing on enhancing immune responses.

Scinai Immunotherapeutics stock price chart

SCNI interactive chart →

SCNI stock quote & key statistics

Scinai Immunotherapeutics earnings per share

Income →
Earnings per share

Scinai Immunotherapeutics revenue & net income

Income →
RevenueNet income

Scinai Immunotherapeutics annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$1.3M-$8.3M—
FY2024$658,000$4.8M-$42.27
FY2023$0-$6.5M-$280.25
FY2022$0-$5.8M—
FY2021$0-$12.4M-$1.15

Fiscal year ending December 31. Source: company filings via EODHD.

About Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd., a biopharmaceutical company in its developmental stages, specializes in advancing, producing, and distributing treatments for infectious and autoimmune diseases across Israel. Leveraging strategic partnerships with the Max Planck Society and University Medical Center Göttingen, Scinai focuses on developing nanosized antibodies (NanoAbs), notably for COVID-19 and other disease indications.

Formerly known as BiondVax Pharmaceuticals Ltd., the company rebranded to Scinai Immunotherapeutics Ltd. in September 2023. Since its inception in 2003, Scinai has been headquartered in Jerusalem, Israel, driving innovation in biopharmaceuticals through its commitment to pioneering research and collaborative initiatives.

Scinai Immunotherapeutics Ltd. was founded with a mission to innovate treatments that address critical medical challenges. With a strong emphasis on research and development, the company continues to expand its portfolio of NanoAbs, aiming to deliver effective solutions that improve public health outcomes worldwide.

Scinai Immunotherapeutics stock FAQ

What is the Scinai Immunotherapeutics stock ticker symbol?

Scinai Immunotherapeutics Ltd. trades on the NASDAQ under the ticker symbol SCNI.

What sector and industry is Scinai Immunotherapeutics in?

Scinai Immunotherapeutics Ltd. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Scinai Immunotherapeutics have?

Scinai Immunotherapeutics Ltd. has about 45 full-time employees.

What were Scinai Immunotherapeutics's revenue and earnings last fiscal year?

Scinai Immunotherapeutics reported revenue of $1.3M and net income of -$8.3M in fiscal 2025. Revenue grew 99.2% from the prior year.

When did Scinai Immunotherapeutics go public?

Scinai Immunotherapeutics stock began trading on May 12, 2015.

Biotechnology stocks

All Healthcare stocks →